Share This Author
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management
The methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn’s disease of this ECCO Consensus are concerns.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.
A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
In a placebo-controlled study of patients with IBS, a low FODMAP diet associates with adequate symptom relief and significantly reduced symptom scores compared with placebo.
Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease
An adequately powered placebo-controlled trial of FOS showed no clinical benefit in patients with active Crohn's disease, despite impacting on DC function.
Effects of Low-FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial.
It is concluded that a 4-week diet low in FODMAPs is safe and effective for managing persistent gut symptoms in patients with quiescent IBD and significant improvements in specific symptom scores and numbers reporting adequate symptom relief are found.
Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials
The present article addresses the clinical evidence for the therapeutic manipulation of bowel microbiota using probiotics, prebiotics and synbiotics in IBD and reviews the role of the intestinal microbiota in the pathogenesis of IBD.